Why Is Suzuki Coupling Still the Core Platform Reaction for Modern API Synthesis, Four Decades Later?

— From an Organic Reaction to the Assembly Interface of the API Supply Chain

One-line summary: Among the many palladium-catalyzed cross-coupling reactions, Suzuki-Miyaura coupling has gradually become the most widely applied in industrial practice, and as a result occupies a central position in modern API processes — it shapes not only route selection, but also which intermediates get procured and whether a process can be scaled to metric-ton production.

ChemAbout's View: Suzuki-Miyaura coupling has gradually evolved from an organic reaction into a platform process within modern small-molecule API development, and on that basis can be regarded as an underlying platform technology of modern pharmaceutical manufacturing. This assessment is built on the reviews, process papers, patents, and regulatory documents listed below; it is ChemAbout's industry analysis, not the direct conclusion of any single publication.

Key Takeaway Published process chemistry reviews list Suzuki-Miyaura coupling as one of the most widely applied palladium-catalyzed coupling reactions in modern pharmaceutical manufacturing, regarding it as one of the most important methods for constructing C(sp2)-C(sp2) bonds in industrial-scale API synthesis and one of the most industrially mature cross-coupling methods — and around it a substantial body of process development experience, impurity-control practice, and a mature building block market have formed [1][2]. Its prevalence is not because it is the fastest-reacting option, but because it offers broad functional group tolerance, comparatively mild conditions, and failure modes that are relatively predictable when scaling from kilogram to metric-ton production.

This article unfolds across five layers: the reaction itself → process scale-up → supply chain structure → procurement decisions → CDMO route development. The first two layers explain "why Suzuki," while the latter three are what this article is really about — how one organic reaction reshaped the way an entire industry is organized.

---

1. From Losartan to Sotorasib: A Cross-Industry Fact Spanning Three Decades

Published process literature shows Suzuki coupling appearing as a key step in drugs approved from the 1990s through the 2020s — spanning ARB-class antihypertensives, BRAF inhibitors, ALK inhibitors, and KRAS inhibitors. What it crosses is not a single therapeutic area, but the small-molecule drug industry as a whole. This span in both time and therapeutic area is itself a notable industry fact, not merely a coincidence of scattered case studies:

• Losartan (approved 1995, ARB-class antihypertensive): Losartan has historically had multiple industrial routes (including Ullmann-type coupling and its modified variants). In some of the published industrial routes, Suzuki coupling has been used to construct the biphenyl-backbone intermediate [3].
• Valsartan (ARB-class antihypertensive): A heterogeneous Suzuki-Miyaura coupling between 2-chlorobenzonitrile and 4-methylphenylboronic acid is the key step that generates the biphenylcarbonitrile intermediate (4'-methyl-2-biphenylcarbonitrile); the scale-up process has been published in Organic Process Research & Development [4].
• Vemurafenib (approved 2011, BRAF inhibitor): A published patent route shows Suzuki coupling between its 7-azaindole core and 4-chlorophenylboronic acid used to construct the molecular scaffold; the patent text itself records that running the reaction in acetonitrile at approximately 170°C generates significant "biphenyl impurity," and that this impurity carries through subsequent synthesis into an impurity difficult to remove from the final product [5].
• Lorlatinib (approved 2018, ALK inhibitor): A published Pfizer process development paper shows its macrocyclic core being closed via an intramolecular Suzuki-Miyaura coupling; during the GMP production campaign, slow addition of the boronate ester suppressed the homocoupling by-product, and the paper reports a substantial improvement in overall process yield relative to earlier routes [6].
• Sotorasib (approved 2021, KRAS G12C inhibitor): In Amgen's published Commercial Manufacturing Process paper, Suzuki-Miyaura coupling is one of the key steps in the synthetic sequence; a companion paper reports kinetic and mechanistic investigations of this step, in which the team changed the rate-determining step and transmetalation pathway by switching the base from KOAc to K2CO3 [7][8].

It should be noted that full details of most commercial routes are not publicly disclosed; the examples above are drawn from published process literature and patents, and do not represent a comprehensive survey of all commercial routes.

ChemAbout's View: This span of time points to a more general phenomenon — modern API synthesis increasingly resembles "modular assembly": two functional fragments are prepared separately, then joined at a late stage via Suzuki coupling. This "building-block-driven" modular design approach has been discussed specifically in the medicinal chemistry literature; it is not a characterization original to this article [9]. It functions more like a standardized interface — a connection protocol that can be called repeatedly across different molecules and different projects: the reaction itself is not the innovation; whether it can be scaled stably and cheaply is.

---

2. Why Did "Assemble Fragments First, Couple Late" Become a Viable Route Design Logic?

Traditional total synthesis builds the scaffold step by step: starting from simple raw materials and constructing the target molecule's carbon framework one step at a time.

Suzuki coupling makes a different design logic possible: Fragment A + Fragment B → late-stage joining.

The value of this design is especially apparent at the Medicinal Chemistry stage:

• It shortens the number of synthetic route steps;
• It makes it easier to swap substituents on the same scaffold for structure-activity relationship (SAR) studies — only the boronic acid or halide fragment needs to change, without redesigning the entire route;
• It fits structural units that appear frequently in drug molecules, such as aromatic rings, nitrogen-containing heterocycles, and biaryl groups.

This is exactly why Suzuki coupling becomes embedded in molecular design logic as early as the drug discovery stage, rather than being a reaction "retrofitted" only once process scale-up begins.

---

3. Among Multiple Cross-Coupling Reactions, Why Does the Pharmaceutical Industry Favor Suzuki?

Pharmaceutical process chemistry is not short on alternatives for carbon-carbon bond formation. At least Stille, Negishi, Kumada, and Ullmann couplings have been systematically compared within the industry, and each exposes different problems during scale-up production:

(Sonogashira coupling is not included in this table because it forms C(sp2)-C(sp) bonds, used to attach terminal alkynes — a different application scenario from the biaryl structures Suzuki addresses, so the two are not in direct competition.)

It is worth noting that Suzuki coupling is not the fastest-reacting cross-coupling reaction — Negishi, Sonogashira, and others can have faster intrinsic reaction rates on certain substrates. But the core metric process scale-up pursues is not reaction speed, it is robustness: whether the process reliably delivers a predictable conversion rate and impurity profile when raw material batches, equipment, or operators change.

ChemAbout's View: The pharmaceutical industry's preference for Suzuki coupling is, at its core, not because it reacts fastest in the lab, but because it exposes comparatively fewer failure modes when scaled from kilogram to metric-ton production, and those failure modes are easier for process engineers to anticipate and control in advance.

---

4. The Core of the Supply Chain: How Suzuki's Large-Scale Adoption and Building Block Commoditization Reinforced Each Other

Before Suzuki coupling was industrialized at scale, an API manufacturer typically had to synthesize every intermediate itself, with the route completed end-to-end, in a closed loop, by a single plant.

The large-scale adoption of Suzuki coupling and the commoditization of building blocks reinforced each other, and together drove the API supply chain's evolution toward modular procurement — this is more accurate than simply saying "Suzuki changed the supply chain": what actually drove this shift was the mutual reinforcement between the two. Suzuki provided a reliable joining method, and the commoditization of boronic acid building blocks in turn made this fragment-based design feasible as early as the medicinal chemistry stage. Published sources show:

• Medicinal chemistry teams procure boronic acid/boronate ester building blocks directly for early scaffold exploration;
• CDMOs, at the route scale-up stage, procure boronic acid intermediates with verified purity and specification rather than synthesizing them from scratch;
• This has supported an independent industry segment — a group of intermediate suppliers dedicated to producing, stocking, and selling boronic acid building blocks. This is exactly why dedicated building block suppliers such as Enamine, Combi-Blocks, Boron Molecular, and Apollo Scientific have been able to grow.

This means that part of the decision-making weight in the API supply chain has shifted from "how to synthesize" to "where to procure which specification of boronic acid/boronate ester fragment."

---

5. Why Did Boronic Acid Intermediates Become Heavily Procured Commodity Fragments?

That a single boron atom can support this much procurement demand comes down to several specific chemical properties:

• Relatively stable and easy to store, unlike organotin or organozinc reagents, which are sensitive to water and oxygen;
• A comparatively wide functional group compatibility window, allowing other reactive groups to coexist on the molecule;
• Already highly commoditized — large numbers of substituted phenylboronic acids and heterocyclic boronic acids can be purchased directly off the shelf, without custom synthesis.

Common commoditized boronic acid/boronate ester fragments on the market include 4-Bromophenylboronic acid, 3-Pyridylboronic acid, and Pinacol Boronate, most of which are already listed as standard catalog procurement items.

Procurement Insight Quotes for the same boronic acid intermediate can differ several-fold across suppliers. The price gap usually is not about the molecule itself, but about assay content, moisture, residual solvents, impurity profile, and metal residue control — and whether the batch meets the buyer's established release specification. These factors directly determine whether a batch can go straight into the process or requires additional re-testing and purification cost.

---

6. Why Is the Real Difficulty Not "Can the Reaction Happen" but "Can It Be Scaled"?

Suzuki coupling generally has a high success rate at milligram-to-gram lab scale. The real challenges emerge after scale-up:

• Palladium residue control: ICH Q3D sets permitted daily exposure (PDE) limits for elemental impurities such as palladium in APIs, based on route of administration, with different limits for different routes; the process scale-up stage typically requires a dedicated palladium-scavenging step to bring residue levels within the ICH Q3D allowance [10].
• Protodeboronation: A 2025 study published in the Journal of the American Chemical Society shows that certain boronic acid intermediates are more prone to protodeboronation under specific substrate structures and ligand systems, and that this process can be accelerated by particular palladium phosphine ligands; the side reaction directly consumes raw material that should have participated in coupling and is a common cause of yield variability, though not all boronic acids are equally sensitive [11].
• Catalyst poisoning: Trace sulfur species in raw materials — sulfides, thiols, thio-compounds — as well as certain nitrogen-heterocycle substrates themselves, can deactivate the palladium catalyst. A GMP campaign case report published in OPRD describes a team tracing an abnormally low conversion rate to trace elemental sulfur in a raw material poisoning the catalyst, ultimately resolved by tightening the raw material's sulfur content specification (≤200 ppm) and applying activated carbon treatment [12].
• Homocoupling: In some palladium-catalyzed systems, free Pd(II) can catalyze boronic acid molecules coupling with one another to form biphenyl-type impurities. Process chemistry literature has specifically reported suppressing this side reaction through controlled addition rate, reductant addition, and nitrogen purging — for example, both Eli Lilly's LY451395 project and Pfizer's Lorlatinib scale-up project used slow addition of the boronate ester to control this impurity [6][13].
• Filtration and purification cost: After scale-up, removing residual palladium and boronic acid by-products is often one of the main factors determining the cost of a single production batch.

This is exactly the part rarely covered in popular science content, yet with the greatest influence on procurement and process decisions: lab-stage yield numbers cannot directly predict the real cost structure of metric-ton production.

---

7. What a Suzuki Coupling Process Procures Is Not Just Boronic Acid

Around a single Suzuki coupling scale-up production run, the real procurement list typically also includes:

• Palladium catalyst: classic ligand systems such as Pd(PPh3)4;
• Phosphine ligands: such as Buchwald-type dialkylbiaryl phosphine ligands (XPhos, SPhos, RuPhos, BrettPhos, JohnPhos, and others), used to improve coupling efficiency for sterically hindered or heterocyclic substrates. Over the past two decades, the development of this ligand family has advanced almost in step with the industrialization of Suzuki coupling, and has been systematically summarized in a review article in Accounts of Chemical Research [14];
• Base: such as K3PO4, Cs2CO3 — the Sotorasib case shows that the choice of base alone can change the reaction mechanism pathway and the cost structure [8];
• Solvent system: such as THF, dioxane, and aqueous co-solvents;
• Inert gas: nitrogen or argon degassing is typically required before the reaction to reduce side reactions involving free oxygen; this gas consumption is likewise part of procurement and cost accounting in industrial-scale production.

Although phosphine ligands and the palladium catalyst are used in far smaller quantities than the boronic acid raw material, they have a large influence on the overall process's conversion rate, by-product profile, and final palladium residue level, which is why they are frequently the variables screened and validated repeatedly during process development.

Procurement Insight The palladium catalyst typically accounts for a small share of raw material cost, but it determines whether the entire process runs stably — batch-to-batch catalyst variation and ligand purity fluctuations show up directly in the conversion rate and impurity profile, which in turn affects downstream purification cost. This is also why changing the palladium catalyst supplier usually requires a fresh round of process validation rather than a simple substitution.

---

8. Why Does Suzuki Coupling Function More Like a Platform Process for Many CDMOs?

Route Scouting work undertaken by CDMOs is, in essence, evaluating which of several candidate routes will most readily pass scale-up validation and enter commercial production; this evaluation typically also weighs Process Mass Intensity (PMI), E-factor (waste generated per unit of product), Raw Material Availability, and Patent Landscape. Published process papers show that "Route Scouting," as a formal process chemistry stage, ultimately feeds into Tech Transfer and Process Performance Qualification (PPQ) [15].

ChemAbout's View: Along these dimensions, Suzuki coupling is often not a "reinvented" route but an existing platform process that gets optimized repeatedly — one with a large accumulated body of scale-up data and impurity-control experience, mature palladium-removal and boronic acid by-product control methods that can be reused directly, and support for Late-Stage Functionalization, which makes it easy to swap substituents quickly during clinical stages without changing the overall route backbone. For many CDMOs, this means route design for a new molecule increasingly comes down to "at which step to introduce Suzuki coupling," rather than "whether to use Suzuki coupling at all."

---

9. Current State of the Boronic Acid / Palladium Catalyst Supply Chain

Publicly available industry data show that China has become one of the world's most important supply clusters for boronic acid building blocks. Behind this pattern lies a stacking of supply-chain factors: boronic acid intermediates are multi-step reaction products requiring substantial fine-chemical production support (boron sources, halogenated arene raw materials, purification equipment); the downstream off-the-shelf procurement model for building blocks further amplifies demand for stable, large-scale capacity; and palladium catalysts and ligands, while carrying a higher unit price and lower volume, likewise depend on fine-chemical contract manufacturing capacity.

---

10. Why Has No Other Reaction Truly Replaced Suzuki?

Suzuki coupling was first reported in 1979. Published process literature shows it has not faded with time — instead, it continues to appear in process papers for drugs recently approved or in late-stage development:

• Sotorasib (KRAS G12C inhibitor, approved 2021): Both Amgen's 2023 commercial manufacturing process paper and its companion kinetic/mechanistic study paper center on a Suzuki coupling step [7][8].
• A key intermediate of Abemaciclib: A 2024 process paper optimized the Miyaura borylation/Suzuki coupling process used in synthesizing this intermediate (note: this is an intermediate synthesis route, not the final step of the API itself) [16].
• A 2025 process paper on the antiviral candidate Onradivir also used a "one-pot" Miyaura-Suzuki coupling as one of its core steps — listed here as a recent research example, not as standalone proof of the reaction's continued importance [17].

In recent years, biologics, ADCs, and oligonucleotide therapies have drawn increasing industry attention, but the published process literature above indicates Suzuki coupling has not exited the small-molecule API process stage as a result — Sotorasib's 2021 approval, along with process-optimization papers still being published in 2024-2025, both indicate it remains in active use and under active optimization.

ChemAbout's View: That Suzuki coupling has not been replaced does not mean it has no limitations — the real scale-up difficulties listed above, protodeboronation, homocoupling, catalyst poisoning, are real. Rather, no other cross-coupling reaction has yet formed a comprehensive replacement across the combined industrial performance dimensions of functional group tolerance, scale-up robustness, and impurity controllability. These recent cases also suggest a possible explanation: modern API molecular design itself increasingly relies on structural units such as biaryl groups and nitrogen-containing heterocycles, and these happen to be exactly the substrate types Suzuki coupling handles best. As long as this molecular design trend continues, Suzuki coupling will most likely remain the default option, not a backup one.

---

11. Misconception FAQ

Is Suzuki coupling an "all-purpose" ring-forming/bond-forming reaction? No. It is specifically used to construct C(sp2)-C(sp2) bonds (primarily biaryl-type structures); its coupling capability and efficiency at sp3 carbon centers is generally weaker than at sp2 substrates, and the specific applicable scope depends on substrate structure.

Are all boronic acid intermediates stable enough for long-term stocking? Not necessarily. Some boronic acids (particularly heterocyclic boronic acids and ortho-substituted boronic acids) are moisture-sensitive under certain conditions and prone to protodeboronation; storage and transport conditions directly affect usable purity on arrival, though not all boronic acids are equally sensitive.

How should one choose between Pinacol Boronate and Boronic Acid? The two are different forms of the same class of coupling partner, each with its own use case: Boronic Acid is generally more reactive with faster transmetalation, but certain structures are more sensitive to moisture and storage conditions and prone to protodeboronation or self-condensation; Pinacol Boronate generally has better physicochemical stability, making it easier to store and transport long-term, but may require an additional hydrolysis step to participate in transmetalation during coupling. The specific choice depends on substrate stability and process conditions, not a fixed hierarchy of advantage.

Can Boronic Acid and BPin be directly substituted for one another? No, they cannot simply be swapped. Their transmetalation rates and applicable reaction conditions (base, solvent, catalyst system) generally differ, and substitution requires re-validating conditions for the specific reaction rather than a simple equimolar swap.

Is switching to a different boronic acid supplier just a matter of finding a lower quote? Not entirely. Batch-to-batch assay content, moisture, and impurity profile directly affect the process's conversion rate and downstream purification burden; a supplier change is usually accompanied by a round of re-validation.

---

12. ChemAbout Insight

What Suzuki coupling has really changed is not any single reaction.

ChemAbout's View: It has changed the way modern drug manufacturing is organized. When a complex molecule can be broken down into multiple independently procurable functionalized fragments and reassembled at the end of synthesis, drug development begins to become modular, API route development begins to become platform-based, and the global supply chain organized around boronic acids, palladium catalysts, and building blocks has formed its own industry structure as a result.

Today, when the industry discusses Suzuki-Miyaura coupling, the discussion is no longer just about a Nobel Prize-winning reaction, but about a platform technology underpinning modern small-molecule API development.

What Suzuki coupling has truly standardized is not just a reaction, but how modern small-molecule drugs are manufactured.

---

References

The evidence is organized into three tiers: peer-reviewed literature (academic reviews and process papers), patent literature, and regulatory guidelines, each labeled individually below.

1. Miyaura, N.; Suzuki, A. Palladium-Catalyzed Cross-Coupling Reactions of Organoboron Compounds. Chem. Rev. 1995, 95, 2457–2483. (Peer-reviewed) https://pubs.acs.org/doi/10.1021/cr00039a007
2. A retrospective-prospective review of Suzuki–Miyaura reaction: From cross-coupling reaction to pharmaceutical industry applications. Journal of Organometallic Chemistry. (Peer-reviewed) https://www.sciencedirect.com/science/article/abs/pii/S0277538722004764
3. Molecular sieves-supported palladium(II) catalyst: Suzuki coupling of chloroarenes and an easy access to useful intermediates for the synthesis of irbesartan, losartan and boscalid. Tetrahedron. (Peer-reviewed) https://www.sciencedirect.com/science/article/abs/pii/S0040402010001948
4. Greening the Valsartan Synthesis: Scale-up of Key Suzuki–Miyaura Coupling over SiliaCat DPP-Pd. Org. Process Res. Dev. (Peer-reviewed) https://pubs.acs.org/doi/abs/10.1021/op400118f
5. WO2015075749A1 — Novel processes for the preparation of vemurafenib. Google Patents. (Patent) https://patents.google.com/patent/WO2015075749A1/en
6. Exploratory Process Development of Lorlatinib. Org. Process Res. Dev. 2019. (Peer-reviewed) https://pubs.acs.org/doi/abs/10.1021/acs.oprd.8b00210
7. Development of a Commercial Manufacturing Process for Sotorasib, a First-in-Class KRAS^G12C Inhibitor. Org. Process Res. Dev. 2023. (Peer-reviewed) https://pubs.acs.org/doi/abs/10.1021/acs.oprd.2c00249
8. Kinetic and Mechanistic Investigations to Enable a Key Suzuki Coupling for Sotorasib Manufacture — What a Difference a Base Makes. Org. Process Res. Dev. 2023. (Peer-reviewed) https://pubs.acs.org/doi/10.1021/acs.oprd.2c00332
9. Quick Building Blocks (QBB): An Innovative and Efficient Business Model To Speed Medicinal Chemistry Analog Synthesis. PMC. (Peer-reviewed) https://pmc.ncbi.nlm.nih.gov/articles/PMC6691476/
10. ICH Q3D (R2) Guideline for Elemental Impurities — establishes permitted daily exposure (PDE) limits for elemental impurities such as palladium (Pd), based on route of administration. (Regulatory guideline)
11. Ser, C. T. et al. Bulky Phosphine Ligands Promote Palladium-Catalyzed Protodeboronation. J. Am. Chem. Soc. 2025. (Peer-reviewed) https://pubs.acs.org/doi/10.1021/jacs.5c14153
12. Identification and Elimination of an Unexpected Catalyst Poison in Suzuki Coupling. Org. Process Res. Dev. (Peer-reviewed) https://pubs.acs.org/doi/abs/10.1021/acs.oprd.7b00342
13. Suppression of a Palladium-Mediated Homocoupling in a Suzuki Cross-Coupling Reaction: Development of an Impurity Control Strategy Supporting Synthesis of LY451395. Org. Process Res. Dev. (Peer-reviewed) https://pubs.acs.org/doi/abs/10.1021/op060180i
14. Palladium-Catalyzed Suzuki−Miyaura Cross-Coupling Reactions Employing Dialkylbiaryl Phosphine Ligands. Acc. Chem. Res. (Peer-reviewed) https://pubs.acs.org/doi/10.1021/ar800036s
15. Adagrasib's Second-Generation Synthesis: Transitioning from Route Scouting to Optimization. Org. Process Res. Dev. 2024. (Peer-reviewed) https://pubs.acs.org/doi/10.1021/acs.oprd.4c00024
16. Optimized Synthesis of an Abemaciclib Intermediate: Improved Conditions for a Miyaura Borylation/Suzuki Coupling Process. Org. Process Res. Dev. 2024. (Peer-reviewed) https://pubs.acs.org/doi/10.1021/acs.oprd.4c00381
17. Development of an Optimized Synthetic Process for Onradivir Featuring a "One-Pot" Miyaura–Suzuki Coupling Reaction. Org. Process Res. Dev. 2025. (Peer-reviewed) https://pubs.acs.org/doi/10.1021/acs.oprd.5c00175